Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of Neonatal Acellular Pertussis Vaccination
NCT00289796Phase 2Completed
- Sponsor
- GSK
- Start
- Jul 2004
- Primary completion
- Apr 2006
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of acellular pertussis vaccine in pertussis (2 arms), sponsored by GSK. Primary endpoints: Number of seropositive subjects for anti-pertussis toxoids (PT) antibodies, Number of seropositive subjects for anti-filamentous hemagglutinin (FHA) antibodies and 13 more. Started Jul 2004; status: completed.
02
Drugs
acellular pertussis vaccine
03
Conditions
pertussis
Beyond the preview
Go deeper on NCT00289796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00289796.